ACT Announces Second Stargardt’s Disease Patient Treated with Higher Dosage of Embryonic Stem Cell-Derived Retinal Pigment

  ACT Announces Second Stargardt’s Disease Patient Treated with Higher Dosage
  of Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells

     Fifth Patient in U.S. Clinical Trial Injected with 100,000 RPE Cells

Business Wire

MARLBOROUGH, Mass. -- October 18, 2012

Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of
regenerative medicine, today announced treatment of the fifth patient, the
second in the second patient cohort, in its U.S. clinical trial for
Stargardt’s Macular Dystrophy (SMD). The patient was injected with 100,000
human embryonic stem cell-derived retinal pigment epithelial (RPE) cells, as
compared with the 50,000 cell dose used in the three patients of the first
cohort. The patient successfully underwent the outpatient transplantation
surgery yesterday, and is recovering uneventfully.

“We continue to make steady progress in our ongoing clinical trials,”
commented Gary Rabin, chairman and CEO. “We look forward to completing the
third and final patient in this cohort in the U.S. clinical trial for SMD in
the near future, which will mark the halfway point. We have now mapped out the
series of patients to complete this cohort and the second cohort in the
European trial, and have done the same in the US AMD trial, pending DSMB
review. With all four trial centers in the US and both trial centers in the UK
now trained and ready to treat patients, combined with the streamlined process
in the European trial protocol, we anticipate an accelerated pace of
generating patient data.”

Initiated in July of last year, the Phase I/II trial is designed to determine
the safety and tolerability of hESC-derived RPE cells following sub-retinal
transplantation in patients with SMD at 12 months, the study’s primary
endpoint. It will involve a total of 12 patients, with cohorts of three
patients each in an ascending dosage format. The company is concurrently
conducting a second trial for SMD in Europe and another for dry age-related
macular degeneration in the U.S.

“We continue to be very encouraged with how this clinical trial is
progressing,” said Robert Lanza, M.D., chief scientific officer. “We are
confident of continued momentum in our other two trials, as well.”

Further information about patient eligibility for ACT’s SMD study and the
concurrent studies in the U.S. and Europe (for dry age-related macular
degeneration and SMD, respectively) are available at www.clinicaltrials.gov,
with the following Identifiers: NCT01345006 (U.S. SMD), NCT01344993 (dry AMD),
and NCT01469832 (E.U. SMD).

About Stargardt’s Disease

Stargardt’s disease or Stargardt’s Macular Dystrophy is a genetic disease that
causes progressive vision loss, usually starting in children between 10 to 20
years of age. Eventually, blindness results from photoreceptor loss associated
with degeneration in the pigmented layer of the retina, called the retinal
pigment epithelium, which is the site of damage that the company believes the
hESC-derived RPE may be able to target for repair after administration.

About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc. is a biotechnology company applying cellular
technology in the field of regenerative medicine. For more information, visit
http://www.advancedcell.com.

Forward-Looking Statements

Statements in this news release regarding future financial and operating
results, future growth in research and development programs, potential
applications of our technology, opportunities for the company and any other
statements about the future expectations, beliefs, goals, plans, or prospects
expressed by management constitute forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Any
statements that are not statements of historical fact (including statements
containing the words “will,” “believes,” “plans,” “anticipates,” “expects,”
“estimates,” and similar expressions) should also be considered to be
forward-looking statements. There are a number of important factors that could
cause actual results or events to differ materially from those indicated by
such forward-looking statements, including: limited operating history, need
for future capital, risks inherent in the development and commercialization of
potential products, protection of our intellectual property, and economic
conditions generally. Additional information on potential factors that could
affect our results and other risks and uncertainties are detailed from time to
time in the company’s periodic reports, including the report on Form 10-K for
the year ended December 31, 2011. Forward-looking statements are based on the
beliefs, opinions, and expectations of the company’s management at the time
they are made, and the company does not assume any obligation to update its
forward-looking statements if those beliefs, opinions, expectations, or other
circumstances should change. Forward-looking statements are based on the
beliefs, opinions, and expectations of the company’s management at the time
they are made, and the company does not assume any obligation to update its
forward-looking statements if those beliefs, opinions, expectations, or other
circumstances should change. There can be no assurance that the Company’s
clinical trials will be successful.

Contact:

Investors:
CEOcast, Inc.
James Young, 212-732-4300
or
Press:
ACT Corporate Communications
Bill Douglass, 646-450-3615
or
Russo Partners
Martina Schwarzkopf, Ph.D., 212-845-4292
 
Press spacebar to pause and continue. Press esc to stop.